Your browser doesn't support javascript.
loading
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study.
Bai, Xue; Shoushtari, Alexander N; Betof Warner, Allison; Si, Lu; Tang, Bixia; Cui, Chuanliang; Yang, Xiaoling; Wei, Xiaoting; Quach, Henry T; Cann, Christopher G; Zhang, Michael Z; Pallan, Lalit; Harvey, Catriona; Kim, Michelle S; Kasumova, Gyulnara; Sharova, Tatyana; Cohen, Justine V; Lawrence, Donald P; Freedman, Christine; Fadden, Riley M; Rubin, Krista M; Frederick, Dennie T; Flaherty, Keith T; Long, Georgina V; Menzies, Alexander M; Sullivan, Ryan J; Boland, Genevieve M; Johnson, Douglas B; Guo, Jun.
Afiliación
  • Bai X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China.
  • Shoushtari AN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Betof Warner A; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
  • Si L; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
  • Tang B; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China.
  • Cui C; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China.
  • Yang X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China.
  • Wei X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China.
  • Quach HT; Department of Medical Oncology, Shanxi Bethune Hospital, Shanxi, China.
  • Cann CG; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China.
  • Zhang MZ; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Pallan L; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Harvey C; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Kim MS; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Kasumova G; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Sharova T; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Cohen JV; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Lawrence DP; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Freedman C; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Fadden RM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Rubin KM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Frederick DT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Flaherty KT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Long GV; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Menzies AM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Sullivan RJ; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Boland GM; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Johnson DB; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Guo J; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Br J Dermatol ; 187(3): 401-410, 2022 09.
Article en En | MEDLINE | ID: mdl-35293617
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Observational_studies / Risk_factors_studies Aspecto: Determinantes_sociais_saude Límite: Humans Idioma: En Revista: Br J Dermatol Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Observational_studies / Risk_factors_studies Aspecto: Determinantes_sociais_saude Límite: Humans Idioma: En Revista: Br J Dermatol Año: 2022 Tipo del documento: Article País de afiliación: China